A novel derivative of cholic acid which acts as a potent and selective FXR agonist (EC50= 99nM) displaying anticholeretic activity in an in vivo rat model of cholestasis. It not only inhibits vascular smooth muscle cell inflammation and migration but also promotes adipocyte differentiation and regulates adipose cell function in vivo.
Product Details
| Alternative Name: | 6-Ethylchenodeoxycholic acid, 3α,7α-Dihydroxy-6α-ethyl-5β-cholan-24-oic acid, Obeticholic acid |
| |
| Formula: | C26H44O4 |
| |
| MW: | 420.6 |
| |
| CAS: | 459789-99-2 |
| |
| Purity: | ≥97% (TLC) |
| |
| Appearance: | White solid. |
| |
| Solubility: | Soluble in DMSO (35mg/ml) or 100% ethanol (25mg/ml). |
| |
| Shipping: | Blue Ice |
| |
| Long Term Storage: | -20°C |
| |
| Use/Stability: | Store solutions at -20°C for up to 3 months. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
A novel diet-induced murine model of steatohepatitis with fibrosis for screening and evaluation of drug candidates for nonalcoholic steatohepatitis: C. Ejima, et al.; Physiol. Rep.
4, 21 (2016),
Abstract;
Full Text
Farnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration: Y.T. Li, et al.; Arterioscler. Thromb. Vasc. Biol.
27, 2606 (2007),
Abstract;
The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo: G. Rizzo, et al.; Mol. Pharmacol.
70, 1164 (2006),
Abstract;
Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis: S. Fiorucci, et al.; J. Pharmacol. Exp. Ther.
313, 604 (2005),
Abstract;
